UnitedHealth, Cigna, CVS sue FTC over insulin litigation process
The three companies are claiming the FTC’s suit is unconstitutional because it was lodged in the agency’s administrative court, instead of a federal one.
CMS allows five states to adopt multi-year continuous Medicaid eligibility for children
The future of such policies is unclear under an upcoming Trump administration, which could rescind approvals or prevent states from implementing waivers.
Oak Street Health co-founder departs CVS
Mike Pykosz, who joined CVS with its acquisition of the value-based medical chain in 2023, is departing amid a flurry of high-level ousters at the struggling company. However, Pykosz is leaving voluntarily, CVS said.
CareMax, dragged by Steward, files for bankruptcy
CareMax was the exclusive Medicare managed service organization to Stewardship Health. Steward’s bankruptcy posed an “existential threat” that CareMax said it couldn’t overcome.
Providence names new COO
Darryl Elmouchi will take on the role effective Jan. 2 as Providence reshuffles its executive team.
Healthcare industry braces for RFK Jr.
Kennedy’s views on vaccines in particular are causing alarm among some physicians and investors.
Trump nominates Dr. Oz to oversee Medicare, Medicaid as CMS head
On Truth Social, President-elect Donald Trump said Oz, who is best known for his eponymous TV show, would take on the “illness industrial complex.”
If enhanced ACA subsidies expire, 4M could become uninsured: report
The enhanced premium tax credits will expire at the end of next year without action from lawmakers. Republicans have previously criticized the subsidies’ cost.
HHS facing challenges as lead agency for healthcare cybersecurity: GAO
The department hasn’t implemented some policies recommended by the watchdog, which could pose a risk to cybersecurity in the sector as attacks increase, according to the Government Accountability Office.
Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.